ADORA2A and Alzheimer disease: Conversely, the blockade of A2AR, with either caffeine or more selective antagonists (SCH 58261, KW6002, or MSX-3), prevents hippocampus-dependent memory deficits and LTP impairments in aged animals [32, 33] and in several AD models [34–37].